Adalimumab injection [humira] (DrugBank: Adalimumab)
16 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
19 | Lysosomal storage disease | 1 |
37 | Generalised pustular psoriasis | 0 |
40 | Takayasu arteritis | 0 |
41 | Giant cell arteritis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
56 | Behcet disease | 0 |
84 | Sarcoidosis | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
151 | Rasmussen encephalitis | 0 |
160 | Congenital ichthyosis | 0 |
164 | Oculocutaneous albinism | 0 |
222 | Primary nephrotic syndrome | 0 |
226 | Interstitial cystitis with Hunners ulcer | 0 |
269 | Pyogenic arthritis | 0 |
271 | Ankylosing spondylitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03153319 (ClinicalTrials.gov) | June 5, 2017 | 11/5/2017 | Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I and II | Phase 1/2 Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I and II | Mucopolysaccharidosis I;Mucopolysaccharidosis II | Drug: Adalimumab Injection [Humira];Drug: Saline Solution for Injection | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | NULL | Recruiting | 5 Years | N/A | All | 14 | Phase 1;Phase 2 | United States |